Literature DB >> 23649300

[Why rheumatoid arthritis needs cardiologists].

H Pieringer1, U C Hoppe.   

Abstract

Rheumatoid arthritis (RA) is associated with a shortened life expectancy. Most premature deaths are caused by cardiovascular (CV) events; therefore it is of importance to consider the increased CV risk when treating RA patients. Traditional CV risk factors cannot fully explain the increased risk but the common understanding is that inflammation significantly contributes to the excess risk observed. Without the use of correction factors commonly used risk calculators underestimate the true CV risk in RA patients. Methotrexate and TNF inhibitors appear to be beneficial with regard to the CV risk. To date there are only few recommendations for interventions in the CV system of RA patients which go beyond those formulated for the general population. The present manuscript summarizes the published evidence concerning the increased CV risk in RA patients.

Entities:  

Mesh:

Year:  2013        PMID: 23649300     DOI: 10.1007/s00393-013-1198-6

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  22 in total

1.  Initiation and adherence to secondary prevention pharmacotherapy after myocardial infarction in patients with rheumatoid arthritis: a nationwide cohort study.

Authors:  Jesper Lindhardsen; Ole Ahlehoff; Gunnar Hilmar Gislason; Ole Rintek Madsen; Jonas Bjerring Olesen; Christian Torp-Pedersen; Peter Riis Hansen
Journal:  Ann Rheum Dis       Date:  2012-03-08       Impact factor: 19.103

Review 2.  Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review.

Authors:  Sarah L Westlake; Alexandra N Colebatch; Janis Baird; Nick Curzen; Patrick Kiely; Mark Quinn; Ernest Choy; Andrew J K Ostor; Christopher J Edwards
Journal:  Rheumatology (Oxford)       Date:  2010-11-11       Impact factor: 7.580

3.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.

Authors:  M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2009-09-22       Impact factor: 19.103

4.  Rheumatoid arthritis is an independent risk factor for an increased augmentation index regardless of the coexistence of traditional cardiovascular risk factors.

Authors:  Herwig Pieringer; Tobias Brummaier; Michael Schmid; Max Pichler; Avida Hayat-Khayyati; Stefan Ebner; Georg Biesenbach; Erich Pohanka
Journal:  Semin Arthritis Rheum       Date:  2012-04-03       Impact factor: 5.532

Review 5.  Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease.

Authors:  Renata Micha; Fumiaki Imamura; Moritz Wyler von Ballmoos; Daniel H Solomon; Miguel A Hernán; Paul M Ridker; Dariush Mozaffarian
Journal:  Am J Cardiol       Date:  2011-08-17       Impact factor: 2.778

6.  Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis.

Authors:  Cynthia S Crowson; Eric L Matteson; Veronique L Roger; Terry M Therneau; Sherine E Gabriel
Journal:  Am J Cardiol       Date:  2012-04-20       Impact factor: 2.778

7.  The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years.

Authors:  Paulo J Nicola; Hilal Maradit-Kremers; Véronique L Roger; Steven J Jacobsen; Cynthia S Crowson; Karla V Ballman; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2005-02

8.  C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.

Authors:  Paul M Ridker; Nina P Paynter; Nader Rifai; J Michael Gaziano; Nancy R Cook
Journal:  Circulation       Date:  2008-11-09       Impact factor: 29.690

Review 9.  The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review.

Authors:  Sarah L Westlake; Alexandra N Colebatch; Janis Baird; Patrick Kiely; Mark Quinn; Ernest Choy; Andrew J K Ostor; Christopher J Edwards
Journal:  Rheumatology (Oxford)       Date:  2009-11-27       Impact factor: 7.580

10.  Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease.

Authors:  Anne Grete Semb; Tore K Kvien; David A DeMicco; Rana Fayyad; Chuan-Chuan Wun; John C LaRosa; John Betteridge; Terje R Pedersen; Ingar Holme
Journal:  Arthritis Rheum       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.